第 1 到 87 筆結果,共 87 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions | Marshall, Alison D; Willing, Alex R; Kairouz, Abe; Cunningham, Evan B; Wheeler, Alice; O'Brien, Nicholas; Perera, Vidura; Ward, John W; Hiebert, Lindsey; Degenhardt, Louisa; Hajarizadeh, Behzad; Colledge, Samantha; Hickman, Matthew; Jawad, Danielle; Lazarus, Jeffrey V; Matthews, Gail V; Scheibe, Andrew; Vickerman, Peter; Dore, Gregory J; Grebely, Jason; JIA-HORNG KAO et al. | The lancet. Gastroenterology & hepatology | 2 | ||
2 | 2024 | Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases | Cheng, Pin-Nan; WEN-JONE CHEN ; Hou, Charles Jia-Yin; Lin, Chih-Lin; Chang, Ming-Ling; Wang, Chia-Chi; Chang, Wei-Ting; Wang, Chao-Yung; Lin, Chun-Yen; Hung, Chung-Lieh; Peng, Cheng-Yuan; Yu, Ming-Lung; Chao, Ting-Hsing; Huang, Jee-Fu; Huang, Yi-Hsiang; Chen, Chi-Yi; Chiang, Chern-En; Lin, Han-Chieh; Li, Yi-Heng; TSUNG-HSIEN LIN ; JIA-HORNG KAO ; TZUNG-DAU WANG ; Liu, Ping-Yen; YEN-WEN WU ; CHUN-JEN LIU | Clinical and molecular hepatology | 1 | ||
3 | 2024 | The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review | SHANG-CHIN HUANG ; JIA-HORNG KAO | The Kaohsiung journal of medical sciences | 1 | ||
4 | 2023 | Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm | Hsu, Yao-Chun; Tseng, Cheng-Hao; JIA-HORNG KAO | Clinical and molecular hepatology | 4 | 0 | |
5 | 2023 | Acute hepatitis C virus infection: clinical update and remaining challenges | CHEN-HUA LIU ; JIA-HORNG KAO | Clinical and molecular hepatology | 6 | 5 | |
6 | 2023 | Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection | Lin, Chih-Lin; JIA-HORNG KAO | Clinical and molecular hepatology | 6 | 2 | |
7 | 2022 | Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection | CHEN-HUA LIU ; JIA-HORNG KAO | Diagnostics (Basel, Switzerland) | 1 | 1 | |
8 | 2022 | Paradigm shift in the treatment options of hepatocellular carcinoma | TUNG-HUNG SU ; SHIH-JER HSU ; JIA-HORNG KAO | Liver international : official journal of the International Association for the Study of the Liver | 22 | 18 | |
9 | 2022 | Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 | CHEN-HUA LIU ; JIA-HORNG KAO | Hepatology International | 7 | 8 | |
10 | 2022 | Advancing the global public health agenda for NAFLD: a consensus statement | Lazarus J.V.; Mark H.E.; Anstee Q.M.; Arab J.P.; Batterham R.L.; Castera L.; Cortez-Pinto H.; Crespo J.; Cusi K.; Dirac M.A.; Francque S.; Hickman I.J.; Hocking S.L.; Hunyady B.; Idilman R.; Isakov V.A.; Jamal M.H.; Jepsen P.; Iskandar N.J.; Song M.J.; Sudhamshu K.C.; George J.; Kakizaki S.; Kalamitsis G.; Kanwal F.; JIA-HORNG KAO ; Kaplan L.; Kawaguchi T.; Khader Y.; Kim S.U.; Kodjoh N.; Koek G.; Hagström H.; Koike K.; Komas N.P.; Korenjak M.; Kugelmas M.; Labidi A.; Lange N.F.; Lavine J.E.; Lazo M.; Lee N.; Lesmana C.R.A.; Huang T.T.-K.; CHUN-JEN LIU ; Long M.T.; Lopez-Jaramillo P.; Malekzadeh R.; Mahtab M.A.; Marchesini G.; Marinho R.; Vázquez S.E.M.; Mateva L.; Nlombi C.M.; Ismail M.H.; Melin P.; Mikolasevic I.; Milovanovic T.; Musso C.; Nakajima A.; Nava E.; Nersesov A.V.; Nikolova D.; Norris S.; Novak K.; Kautz A.; Oben J.; Ong J.P.; Onyekwere C.; Papatheodoridis G.; Paruk I.; Patel K.; Macedo M.P.; Penha-Gonçalves C.; Figueroa M.P.; Hofmann W.P.; Sarin S.K.; Petta S.; de Oliveira C.P.M.S.; Puri P.; Pan C.Q.; Rac M.; Ralston J.; Ramji A.; Razavi H.; Alvares-da-Silva M.R.; Roberts S.; Loomba R.; Roden M.; Rose T.; Rouabhia S.; Rovere-Querini P.; Rowe I.A.; Sadirova S.; Salupere R.; Saparbu T.; Sayegh R.; Sebastiani G.; Miller V.; Seki Y.; Selmo J.; Serme A.K.; Shaw J.E.; Shenoy T.; Sheron N.; Shibolet O.; Silva M.; Skrypnyk I.; Socha P.; Newsome P.N.; Soriano J.; Spearman C.W.; Sridharan K.; Suárez J.J.; Sheriff D.S.; Sung K.-C.; Swain M.; Tacke F.; Taheri S.; Tan S.-S.; Ninburg M.; Tapper E.B.; Yki-Järvinen H.; Thiele M.; Shawa I.T.; Tolmane I.; Torres E.A.; Trauner M.; Treeprasertsuk S.; Turcanu A.; Valantinas J.; Ocama P.; Vesterhus M.; Waked I.; Wild S.H.; Willemse J.; Wong R.J.; Xanthakos S.; Young D.Y.; Yu M.-L.; Zheng K.I.; Zeybel M.; Ratziu V.; Zheng M.-H.; the NAFLD Consensus Consortium; Rinella M.; Romero D.; Romero-Gómez M.; Schattenberg J.M.; Tsochatzis E.A.; Valenti L.; Wong V.W.-S.; Yilmaz Y.; Younossi Z.M.; Zelber-Sagi S.; Åberg F.; Adams L.; Khatry M.S.A.; Naamani K.A.; Murillo O.A.; Allen A.M.; Alnaser F.; Alqahtani S.A.; Alswat K.; Alvaro D.; Andrade R.J.; Arrese M.; Awuku Y.A.; Ayesha M.; Baatarkhuu O.; Bakieva S.; Basu R.; Bataller R.; Bedri S.; Bosi E.; Bourliere M.; Bruha R.; Bugianesi E.; Burra P.; Buti M.; Byrne C.D.; Calleja J.L.; Carrieri P.; Carter F.; Fernandez M.I.C.; Castillo-Lopez G.; Castro-Narro G.E.; Chan H.L.Y.; Chan W.-K.; Chang Y.; Colombo M.; Coppell K.J.; Corey K.; Craxi A.; Cryer D.; Dassanayake A.; Martins A.A.S.; de Ledinghen V.; DelPrato S.; Demaio A.; Desalegn H.; Dillon J.; Duseja A.; Dorairaj P.; Ekstedt M.; El Kassas M.; Elsanousi O.M.; Esmat G.; Fan J.-G.; Farpour-Lambert N.; Flisiak R.; Fouad Y.; Fuchs M.; Gani R.A.; Gerber L.; Ghazinyan H.; Gheorghe L.; Goh G.B.-B.; Grønbæk H.; Gulnara A.; Hamid S.; Hebditch V. | Nature Reviews Gastroenterology and Hepatology | 328 | 283 | |
11 | 2022 | Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B | SHANG-CHIN HUANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 7 | 6 | |
12 | 2022 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data | Lim Y.-S.; Seto W.-K.; Kurosaki M.; Fung S.; JIA-HORNG KAO ; Hou J.; Gordon S.C.; Flaherty J.F.; Yee L.J.; Zhao Y.; Agarwal K.; Lampertico P. | Alimentary Pharmacology and Therapeutics | 12 | 11 | |
13 | 2021 | Prevention of hepatitis b virus-related hepatocellular carcinoma | Lin C.-L.; JIA-HORNG KAO | Hepatoma Research | 15 | 15 | |
14 | 2020 | Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? | SHIH-JER HSU ; Yang S.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 16 | 14 | |
15 | 2020 | Hepatitis B reactivation: diagnosis and management | SHANG-CHIN HUANG ; HUNG-CHIH YANG ; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 18 | 15 | |
16 | 2020 | Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence | Lin C.-L.; JIA-HORNG KAO | Gastroenterology clinics of North America | 15 | 14 | |
17 | 2020 | Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen–Negative Patients: An Asian Perspective | TUNG-HUNG SU ; JIA-HORNG KAO | Clinical Liver Disease | 1 | 0 | |
18 | 2020 | Systematic review: chronic viral hepatitis and metabolic derangement | Wang C.-C.; Cheng P.-N.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 70 | 54 | |
19 | 2020 | East Asia expert opinion on treatment initiation for chronic hepatitis B | JIA-HORNG KAO ; Hu T.-H.; Jia J.; Kurosaki M.; Lim Y.-S.; Lin H.-C.; Sinn D.H.; Tanaka Y.; Wai-Sun Wong V.; Yuen M.-F. | Alimentary Pharmacology and Therapeutics | 42 | 32 | |
20 | 2020 | Hepatitis B virus: Advances in prevention, diagnosis, and therapy | Nguyen M.H.; Wong G.; Gane E.; JIA-HORNG KAO ; Dusheiko G. | Clinical Microbiology Reviews | 246 | 205 | |
21 | 2018 | Sarcopenia and chronic liver diseases | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 74 | 61 | |
22 | 2018 | Review article: the prevention of hepatitis B-related hepatocellular carcinoma | Lin C.-L.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 40 | 35 | |
23 | 2017 | An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia | Hsu C.S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 11 | 11 | |
24 | 2017 | Urgency to treat patients with chronic hepatitis C in Asia | JIA-HORNG KAO ; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; CHEN-HUA LIU ; Paik S.-W. | Journal of Gastroenterology and Hepatology (Australia) | 19 | 18 | |
25 | 2017 | Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model | JIA-HORNG KAO ; Asselah T.; Dou X.-G.; Hamed K. | Journal of Gastroenterology and Hepatology (Australia) | 5 | 6 | |
26 | 2017 | Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants | Lin C.-L.; JIA-HORNG KAO | Best Practice and Research: Clinical Gastroenterology | 133 | 115 | |
27 | 2017 | Unmet Needs in Clinical and Basic Hepatitis B Virus Research | TUNG-HUNG SU ; JIA-HORNG KAO | Journal of Infectious Diseases | 19 | 17 | |
28 | 2017 | Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B | Wei L.; JIA-HORNG KAO | Current Medical Research and Opinion | 14 | 12 | |
29 | 2016 | APASL consensus statements and recommendation on treatment of hepatitis C | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 185 | 167 | |
30 | 2016 | Review article: novel therapies for hepatitis B virus cure – advances and perspectives | Lin C.-L.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 45 | 39 | |
31 | 2016 | Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection | Yang S.-S.; JIA-HORNG KAO | Hepatology International | 8 | 8 | |
32 | 2016 | New perspectives of biomarkers for the management of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Clinical and Molecular Hepatology | 48 | 0 | |
33 | 2016 | Hepatitis B virus: New therapeutic perspectives | Lin C.-L.; HUNG-CHIH YANG ; JIA-HORNG KAO | Liver International | 45 | 36 | |
34 | 2016 | Management of hepatitis C patients with decompensated liver disease | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 5 | 4 | |
35 | 2016 | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 72 | 70 | |
36 | 2016 | Perspectives on dual hepatitis B and C infection in Taiwan | CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 13 | 12 | |
37 | 2016 | How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? | Wang C.-C.; JIA-HORNG KAO | Expert Opinion on Pharmacotherapy | 13 | 11 | |
38 | 2015 | A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan | Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO ; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H. | Hepatology International | 80 | 73 | |
39 | 2015 | Treating Immune-tolerant Hepatitis B | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of viral hepatitis | 39 | 32 | |
40 | 2015 | Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma | Wang C.-C.; JIA-HORNG KAO | Hepatology International | 27 | 27 | |
41 | 2015 | What can we learn from hepatitis B virus clinical cohorts? | Lin C.-L.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Liver International | 11 | 10 | |
42 | 2015 | Perspectives and control of hepatitis B virus infection in Taiwan | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 64 | 62 | |
43 | 2015 | Hepatitis B virus infection and metabolic syndrome: Fact or fiction? | Wang C.-C.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 67 | 64 | |
44 | 2015 | Hepatitis B vaccination and prevention of hepatocellular carcinoma | JIA-HORNG KAO | Best Practice and Research: Clinical Gastroenterology | 80 | 64 | |
45 | 2015 | Improving clinical outcomes of chronic hepatitis B virus infection | TUNG-HUNG SU ; JIA-HORNG KAO | Expert review of Gastroenterology and Hepatology | 26 | 23 | |
46 | 2015 | Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma | Hsu C.-S.; Chao Y.-C.; Lin H.H.; DING-SHINN CHEN ; JIA-HORNG KAO | Scientific Reports | 56 | 46 | |
47 | 2014 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa | CHEN-HUA LIU ; JIA-HORNG KAO | International Journal of Nanomedicine | 33 | 34 | |
48 | 2014 | Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance | HUNG-CHIH YANG ; JIA-HORNG KAO | Emerging Microbes and Infections | 102 | 104 | |
49 | 2014 | Risk stratification of HBV infection in Asia-Pacific region | JIA-HORNG KAO | Clinical and molecular hepatology | 20 | 0 | |
50 | 2014 | HBeAg-positive chronic hepatitis B: Why do I treat my patients with pegylated interferon? | JIA-HORNG KAO | Liver International | 45 | 41 | |
51 | 2014 | Molecular mechanism and treatment of viral hepatitis-related liver fibrosis | TUNG-HUNG SU ; JIA-HORNG KAO ; CHUN-JEN LIU | International Journal of Molecular Sciences | 57 | 52 | |
52 | 2013 | IL28B genotype on HCV infection in Asia | CHEN-HUA LIU ; JIA-HORNG KAO | Current Hepatitis Reports | 3 | 0 | |
53 | 2013 | Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen | TAI-CHUNG TSENG ; JIA-HORNG KAO | Tzu Chi Medical Journal | 3 | 0 | |
54 | 2013 | Hepatitis B virus reactivation in patients receiving cancer chemotherapy: Natural history, pathogenesis, and management | CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology International | 43 | 35 | |
55 | 2013 | Hepatitis B viral factors and treatment responses in chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 34 | 32 | |
56 | 2013 | Global perspective on the natural history of chronic hepatitis B: Role of hepatitis B virus genotypes A to J | CHUN-JEN LIU ; JIA-HORNG KAO | Seminars in Liver Disease | 141 | 125 | |
57 | 2013 | Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology | 103 | 94 | |
58 | 2012 | Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan | Hsu C.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 34 | 30 | |
59 | 2012 | Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; JIA-HORNG KAO ; Lee, Hsuan-Shu ; TIFFANY TING-FANG SHIH | European Radiology | 98 | 83 | |
60 | 2012 | Genomic variation-guided management in chronic hepatitis C | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 9 | 9 | |
61 | 2012 | Advances in the treatment of chronic hepatitis C: From interferon to direct acting anti-virals | CHUN-JEN LIU ; Hsu C.-S.; JIA-HORNG KAO | Journal of Internal Medicine of Taiwan | 1 | ||
62 | 2011 | Hepatitis C virus and lipid profiles: More questions than answers? | Hsu C.-S.; JIA-HORNG KAO | Hepatology International | 2 | 2 | |
63 | 2011 | The clinical implications of hepatitis B virus genotype: Recent advances | Lin C.-L.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 296 | 266 | |
64 | 2011 | Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease | Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO ; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. | Drugs | 21 | 18 | |
65 | 2011 | Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report | Chan H.L.-Y.; Thompson A.; Martinot-Peignoux M.; Piratvisuth T.; Cornberg M.; Brunetto M.R.; Tillmann H.L.; JIA-HORNG KAO ; Jia J.-D.; Wedemeyer H.; Locarnini S.; Janssen H.L.A.; Marcellin P. | Journal of Hepatology | 274 | 247 | |
66 | 2011 | Recent advances in the treatment of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Expert Opinion on Pharmacotherapy | 26 | 26 | |
67 | 2010 | Implications of hepatitis B virus genomic variations on treatment outcomes | TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | Current Pharmacogenomics and Personalized Medicine | 5 | 0 | |
68 | 2010 | Hepatitis B e antigen seroconversion: A critical event in chronic hepatitis B virus Infection | Liaw Y.-F.; Lau G.K.K.; JIA-HORNG KAO ; Gane E. | Digestive Diseases and Sciences | 85 | 74 | |
69 | 2009 | Prevention of hepatocellular carcinoma in hepatitis B virus infection | Lim S.G.; Mohammed R.; Yuen M.-F.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 63 | 61 | |
70 | 2008 | Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis | JIA-HORNG KAO ; DING-SHINN CHEN | Current Hepatitis Reports | 4 | 0 | |
71 | 2008 | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update | Liaw Y.-F.; Leung N.; JIA-HORNG KAO ; Piratvisuth T.; Gane E.; Han K.-H.; Guan R.; Lau G.K.K.; Locarnini S. | Hepatology International | 836 | 748 | |
72 | 2008 | Diagnosis of hepatitis B virus infection through serological and virological markers | JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 106 | 0 | |
73 | 2008 | Hepatitis B viral factors and clinical outcomes of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Journal of Biomedical Science | 89 | 76 | |
74 | 2008 | Genetic variability of hepatitis B virus and response to antiviral therapy | CHUN-JEN LIU ; JIA-HORNG KAO | Antiviral Therapy | 40 | 28 | |
75 | 2007 | Hepatitis B virus genotype: What should the clinician know? | CHUN-JEN LIU ; JIA-HORNG KAO | Current Hepatitis Reports | 6 | 0 | |
76 | 2007 | Hepatitis B virus-related hepatocellular carcinoma: Epidemiology and pathogenic role of viral factors | CHUN-JEN LIU ; JIA-HORNG KAO | Journal of the Chinese Medical Association | 71 | 0 | |
77 | 2006 | HBV genotypes: Epidemiology and implications regarding natural history | JIA-HORNG KAO ; DING-SHINN CHEN | Current Hepatitis Reports | 30 | 0 | |
78 | 2006 | Pegylated interferons for the treatment of chronic hepatitis B. | CHUN-JEN LIU ; JIA-HORNG KAO | Recent patents on anti-infective drug discovery | 5 | 0 | |
79 | 2005 | Therapeutic implications of hepatitis B virus genotypes | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 108 | 82 | |
80 | 2005 | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update | Liaw Y.-F.; Leung N.; Guan R.; Lau G.K.K.; Merican I.; McCaughan G.; Gane E.; JIA-HORNG KAO ; Omata M.; Chutaputti B.A.; DING-SHINN CHEN ; Chien R.N.; Cooksley G.; Han K.H.; Ichida T.; Lai M.Y.; Lesmana L.; Piratvisuth T.; Sarin S.K.; Sollano J.; Suh D.J.; Yao G.B.; Yeh C.T.; Yokosuka O. | Liver International | 334 | 271 | |
81 | 2005 | Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia | JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 100 | 88 | |
82 | 2002 | Recent research progress in hepatocellular carcinoma | JIA-HORNG KAO ; DING-SHINN CHEN | Journal of the Formosan Medical Association | 20 | 21 | |
83 | 2002 | Hepatitis B viral genotypes: Clinical relevance and molecular characteristics | JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 280 | 257 | |
84 | 2002 | Global control of hepatitis B virus infection | JIA-HORNG KAO ; DING-SHINN CHEN | Lancet Infectious Diseases | 714 | 631 | |
85 | 1999 | Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: Implications for occupational health practice | JIA-HORNG KAO ; Heptonstall J.; DING-SHINN CHEN | Occupational and Environmental Medicine | 11 | 9 | |
86 | 1999 | GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease? | JIA-HORNG KAO ; DING-SHINN CHEN | Journal of Biomedical Science | 15 | 0 | |
87 | 1998 | Hepatitis C virus infection in Taiwan | JIA-HORNG KAO ; DING-SHINN CHEN | Chinese Journal of Public Health | 0 |